期刊文献+

重症肌无力的治疗:循证与辨证 被引量:1

The management of myasthenia gravis:evidence-based or pathophysiology-based?
下载PDF
导出
摘要 通过1例重症肌无力(MG)患者的病情分析,提出临床处理需要解决的问题,并对比有关MG治疗的循证医学证据和指南与实际治疗之间存在的差距。经过比较,发现现有的循证医学证据不足以充分解决MG的治疗问题。以上分析提示我们重症肌无力的治疗需要结合循证医学证据,但更需要在充分理解病理生理学的基础上给予合理的治疗。 After the introduction of a cases of myasthenia gravis (MG) , the questions related to clinical management were raised, and the differences between evidence and guidelines on MG management and practical managements were compared. Through comparison, it was found that current evidence-based measures were not enough to solve the problems of clinical management for MG. It is suggested that in addition to the current evidence, we should give reasonable managements on the basis of thorough understanding of the patho- physiology of MG.
出处 《国际神经病学神经外科学杂志》 2009年第3期217-220,共4页 Journal of International Neurology and Neurosurgery
关键词 重症肌无力 循证医学 治疗 病理生理学 myasthenia gravis evidence-based medicine management pathophysiology
  • 相关文献

参考文献15

  • 1Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev, 2002, ( 4 ) : CD002275.
  • 2Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev, 2005, (2): CD002828.
  • 3Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev, 2006, (2) : CD005081.
  • 4Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev, 2007, (4): CD005224.
  • 5Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev, 2008 , (1) : CD002277.
  • 6Benatar M, Kaminski H J, Quality Standards Subcommittee of the American Academy of Neurology. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review ) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2007, 68 (24) : 2144-2149.
  • 7Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis ( an evidence-based review ) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2000, 55 (1): 7-15.
  • 8Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol, 2006, 13(7) : 691-699.
  • 9Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet, 2001, 357(9274): 2122-2128.
  • 10Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology, 2003, 61(12) : 1652-1661.

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部